Literature DB >> 15889356

Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?

Dale N Gerding.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889356     DOI: 10.1086/430317

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  14 in total

1.  In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.

Authors:  Anne-Marie Bourgault; François Lamothe; Vivian G Loo; Louise Poirier
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

2.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

3.  Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay.

Authors:  Daniel M Musher; Atisha Manhas; Pranav Jain; Franziska Nuila; Amna Waqar; Nancy Logan; Bernard Marino; Edward A Graviss
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

4.  Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.

Authors:  Jason G S Ho; Antonio Greco; Maja Rupnik; Kenneth K-S Ng
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

5.  Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial.

Authors:  John S Fordtran
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-01

6.  Current Treatment Options for Severe Clostridium difficile-associated Disease.

Authors:  Edie P Shen; Christina M Surawicz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-02

7.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

8.  Metronidazole resistance in Clostridium difficile is heterogeneous.

Authors:  T Peláez; E Cercenado; L Alcalá; M Marín; A Martín-López; J Martínez-Alarcón; P Catalán; M Sánchez-Somolinos; E Bouza
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

Review 9.  Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

10.  Clostridium difficile--a moving target.

Authors:  Glenn S Tillotson; Joni Tillotson
Journal:  F1000 Med Rep       Date:  2011-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.